SPG302: A Synaptic Regenerative Treatment Option for Schizophrenia

SPG601 found to reduce measure of abnormal brain activity in fragile X

FDA Grants Fast Track Designation to Spinogenix’s SPG601 for Treatment of FXS

FDA Designation for SPG601 Highlights New Hope for FXS Treatment

Novel BK Channel Activator Fast Tracked for Fragile X Syndrome

Personalized medicine; astroglia organoids; fast track for fragile X drug

Spinogenix’s SPG601 Receives FDA Fast Track Designation for Fragile X Syndrome

FDA grants fast-track designation to small molecule for Fragile X

Rewiring the Brain… Dr. Peter Vanderklish, Chief Scientific Officer, Spinogenix

Companies To Watch: Spinogenix
